Tag: filtration

SYDNEY, July 7, 2026 /PRNewswire/ -- Research will be key for Australians heading into Amazon Prime Day this year, hoping to grab a bargain...

AiraBreeze launches 2026 direct-to-consumer evaporative air cooler with energy-efficient operation across US, Canada, UK, EU, and NZ.

ORLANDO, Fla., June 25, 2026 /PRNewswire/ -- Commissioned in April 2026, the new Water Treatment Plant in Chatham, MA helps the Town meet Massachusetts...

LONDON, June 24, 2026 /PRNewswire/ -- The global biochar market is expected to be valued at US$ 910.4 million in 2026 and projected to...

LONDON, June 24, 2026 /PRNewswire/ -- The global biochar market is expected to be valued at US$ 910.4 million in 2026 and projected to...

iSpring Announces Amazon Prime Day 2026 Savings of Up to 40% on Premium Water Filtration Solutions

BALLERUP, Denmark, June 23, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (Nasdaq: LIQT), a clean technology company specializing in advanced filtration technologies, today announced that it has secured a commercial order for four of its marine water treatment systems for commercial vessels utilizing Exhaust Gas Recirculation (EGR) engine technology in China. The first system is scheduled for delivery in Q4 2026. The order highlights the continued commercial adoption of LiqTech's marine water treatment solutions and further strengthens the Company's position in the market for advanced vessel emissions and water treatment technologies.

LONDON, BERLIN and PARIS, June 19, 2026 /PRNewswire/ -- As families across the United Kingdom, Germany, and France transition from Father's Day gatherings into...

NEW YORK, June 18, 2026 /PRNewswire/ -- As more people prioritize comfort, calm, and balance in everyday life, the home environment has become a...

NEW YORK, June 18, 2026 /PRNewswire/ -- FEPPO, a rising leader in innovative home appliances, is thrilled to announce that it's offering up to 38%...

Home-wellness resource ranks nine cold plunge brands across ten best-in-class categories, naming Sun Home Best Overall and Best Portable, with Plunge, Nordic Wave, Tru...

SHERIDAN, Wyo., June 15, 2026 /PRNewswire/ -- The global laboratory filtration market is projected to grow from USD 4.5 billion in 2025 to USD...

iSpring Celebrates Father’s Day with Practical Water Filter Systems for Dad’s Health and Everyday Enjoyment

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.